EUDA Health Holdings announced a financing transaction on December 5 2025, following an agreement entered on November 26. The company sold a convertible warrant to Streeterville Capital for $100,000. The warrant allows up to 2 million shares at an exercise price of $6.00 per share, exercisable in cash within 90 days. The transaction is filed under the company’s Form F‑3 shelf registration.
The warrant includes a forced‑exercise clause that triggers if the share price reaches $7.50 for five consecutive trading days and the cumulative volume over those days exceeds $1.5 million, with a cap of 10 % of the cumulative dollar volume. The clause is designed to secure additional capital if the stock performs well, while keeping dilution deferred until the warrant is exercised.
EUDA’s management said the proceeds will support the expansion of its non‑invasive healthcare services and the development of a biotechnology platform across Asia. CEO Alfred Lim emphasized that the deal strengthens the company’s capital position and provides flexibility to invest in high‑return initiatives such as new centers, partnerships, and technology projects in Singapore, Malaysia, and China.
The company’s recent financial performance shows a 84 % year‑over‑year increase in total revenue, reaching $5.16 million for the trailing twelve months ending June 2025. Despite the revenue growth, EUDA reported net losses in recent periods, reflecting ongoing investment in growth initiatives and the cost of scaling its service and property‑management segments.
EUDA operates in two primary segments: healthcare services and property management. Revenue growth has been driven largely by the healthcare services segment, which benefits from rising demand for preventive and longevity‑focused care in an aging Asian market. The property‑management segment remains a smaller contributor but provides steady cash flow that supports the company’s expansion plans.
The company has previously raised capital through a $1 million convertible note program and a $15 million CK Health share‑based acquisition, indicating a strategy of leveraging flexible financing to fuel growth. The new warrant adds to this mix, offering a low‑cost source of capital that can be converted into equity if the company’s share price appreciates.
EUDA’s market capitalization was approximately $108 million as of December 5, 2025. The warrant financing is a material event that enhances liquidity and positions the company to pursue its strategic objectives without immediate dilution, while providing a potential upside for investors if the share price moves toward the warrant’s exercise price.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.